Korea Arlico Pharm Co.,Ltd.
Financials
Valuation Metrics
Korea Arlico Pharm Co.,Ltd.'s Market Cap is ₩282B. At end of 2025 it was ₩655B. Ranked #2070 of 2,405 in KR market (top 86%), #1324 of 1,627 on KOSDAQ (top 81%), #216 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 28.22B KRW | KR#2,070/2,405 Sec#216/231 |
| Revenue | 195.70B KRW | KR#1,050/2,405 Sec#63/231 |
| Net Income | -2.85B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 170.67B KRW | KR#1,413/2,405 Sec#105/231 |
| Net Assets | 75.86B KRW | KR#1,620/2,405 Sec#132/231 |
| Employees | 242 | KR#946/2,405 Sec#82/231 |
| Value | ||
| P/B | 0.37x | KR#580/2,405 Sec#19/231 |
| P/S | 0.14x | KR#257/2,405 Sec#2/231 |
| FCF Yield | 24.39% | KR#266/2,405 Sec#5/231 |
| Profitability | ||
| ROE | -3.76% | KR#1,743/2,405 Sec#124/231 |
| ROA | -1.67% | KR#1,726/2,405 Sec#121/231 |
| Op. Margin | -4.10% | KR#1,826/2,405 Sec#122/231 |
| Revenue Growth | -3.04% | KR#1,680/2,405 Sec#162/231 |
| Earnings Growth | -1185.70% | KR#1,325/2,405 Sec#94/231 |
| Financial Health | ||
| Debt Ratio | 124.96% | KR#1,746/2,405 Sec#195/231 |
| Total Debt | 11.38B KRW | KR#1,569/2,405 Sec#140/231 |
| FCF | 6.88B KRW | KR#819/2,405 Sec#52/231 |
| Cash | 18.46B KRW | KR#1,289/2,405 Sec#97/231 |
| Current Ratio | 1.03x | KR#1,676/2,405 Sec#170/231 |
| Dividend | ||
| Div. Yield | 4.08% | KR#457/2,405 Sec#18/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -50.91% | KR#1,974/2,405 Sec#171/231 |
| 1M Return | -18.54% | KR#1,788/2,405 Sec#173/231 |
| From 52W High | -68.04% | KR#1,997/2,405 Sec#168/231 |
| 1Y MDD | -63.54% | KR#1,642/2,405 Sec#136/231 |
| Trading | ||
| Volume | 9,029 shares | KR#1,888/2,405 Sec#190/231 |
| Trading Value | 16.7M KRW | KR#2,139/2,405 Sec#218/231 |
| Foreign Own. | 4.34% | KR#974/2,405 Sec#88/231 |
| Per Share | ||
| EPS | -186 KRW | KR—/2,405 Sec—/231 |
| BPS | 4,950 KRW | KR#1,514/2,405 Sec#109/231 |
Company Info
Alico Pharmaceutical, established in 1992, manufactures and sells pharmaceuticals, having been listed on the KOSDAQ market in 2018. Its core businesses encompass domestic pharmaceutical sales, contract manufacturing organization (CMO), export of pharmaceuticals and goods, and the development and sale of medical devices, health functional foods, and cosmetics. The company has achieved external growth and profitability by focusing on profitable specialized pharmaceutical renewals, efficient production systems, and a low-cost, high-efficiency sales network. Alico Pharmaceutical is headquartered in Seocho-gu, Seoul.